Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Hannah R. Sullivan and Scott J. Schweikart, JD, MBE
Legal questions regarding clinicians’ and technology manufacturers’ liability arise when algorithmic recommendations generated by the technology are hard to understand.
AMA J Ethics. 2019;21(2):E160-166. doi:
10.1001/amajethics.2019.160.